Knockout phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG) increased CD8+ T cell infiltration and programmed death 1 (PD-1) expression in T cells in the tumour microenvironment; thus, inhibiting p110γ enhanced the efficacy of anti-programmed cell death ligand 1 (PD-L1) immunotherapy in head and neck squamous cell carcinoma by modulating host immune activity against tumour cytotoxicity and increasing the expression of immunosuppressive markers (Anderson et al. 2021). Here, PIK3CG is linked to neoplasm.